A recent systematic review found no clear evidence that rheumatoid arthritis patients treated with cyclophosphamide have better lung function than those treated with mycophenolate mofetil. The researchers caution that physicians should expect treatment with cyclophosphamide may only result in a modest improvement in the preservation of forced vital capacity…
New research examined the link between a reduction in serum uric acid (SUA) levels and the reduced risk of renal function decline in patients with gout. The findings suggest that aggressive serum acid-lowering approaches may be helpful in slowing the progression of renal disease…
NEW YORK (Reuters Health)—Tai chi improves fibromyalgia symptoms at least as effectively as aerobic exercise, according to a new trial. Aerobic exercise is the most commonly recommended non-drug treatment for fibromyalgia, Dr. Chenchen Wang of Tufts University School of Medicine in Boston and her colleagues note in The BMJ, online March 12.1 However, Dr. Wang…
NEW YORK (Reuters Health)—Abaloparatide appears to be a safe and effective drug for increasing bone mineral density (BMD) in women 80 and older, new research shows. The study is a post hoc analysis of the Abaloparatide Comparator Trial in Vertebral Endpoints (ACTIVE) trial, which found patients who received abaloparatide subcutaneously for 18 months had increased…
NEW YORK (Reuters Health)—After discontinuation of teriparatide, increases in bone mineral density (BMD) are greater with denosumab than with zoledronic acid, but whether that translates into a decreased fragility fracture risk remains unknown, researchers say. Teriparatide was the first anabolic treatment approved for osteoporosis in the U.S. It has been shown to increase BMD, and…
In this review, the authors address the key pathophysiologic mechanisms that drive acute and chronic chikungunya arthritis, arguably the most incapacitating sequela among long-lasting chikungunya virus disease manifestations, based on recent animal experimental disease models and epidemiologic studies. They explore the latest findings in therapeutic development aimed at limiting viral spread and at immune and…
A recent study found that dermatology patients taking long-term steroids are not always evaluated for steroid-induced osteoporosis…
NEW YORK (Reuters Health)—The selective Janus kinase 1 and 2 inhibitor baricitinib appears also to help patients whose rheumatoid arthritis (RA) has not responded adequately to biologic disease-modifying antirheumatic drugs, according to results from the RA-BEACON randomized trial. The previously published overall results from RA-BEACON showed that baricitinib-treated patients had significantly better functional and clinical…
Approximately 16% of patients diagnosed with Takayasu’s arteritis (TA) experience a stroke. In a recent study, researchers found patients with TA and stroke had higher levels of C-reactive protein at diagnosis…
Two Phase 3 clinical trials show that risankizumab is effective for achieving skin clearance in patients with psoriasis…